Thiol-inducing and immunoregulatory effects of flavonoids in peripheral blood mononuclear cells from patients with end-stage diabetic nephropathy

Free Radical Biology and Medicine

Volumn 33, Issue 10, 2002, Pages 1347-1354

  Dietzmann, Jörn ^a   Thiel, Ute ^a   Ansorge, Siegfried ^a   Neumann, Klaus Hinrich ^a   Tüger, Michael ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Diabetic nephropathy; Flavonoids; Free radicals; Silibinin; T cell activation; Thiols

Indexed keywords

CD69 ANTIGEN; FLAVONOID; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 5; POKEWEED MITOGEN; SILIBININ; SILYMARIN; THIOL DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; FREE RADICAL; LEUKOCYTE ANTIGEN; T LYMPHOCYTE ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CELL LEVEL; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIABETIC NEPHROPATHY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HEMODIALYSIS; HUMAN; HUMAN CELL; IMMUNOREGULATION; KIDNEY FAILURE; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; SUPERNATANT; T LYMPHOCYTE ACTIVATION; BIOSYNTHESIS; BLOOD; KINETICS; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; PATHOLOGY; TIME;

PHYTOLACCACEAE;

AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CYTOKINES; DIABETIC NEPHROPATHIES; FEMALE; FLAVONOIDS; FLOW CYTOMETRY; FREE RADICALS; HUMANS; KINETICS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; POKEWEED MITOGENS; SILYMARIN; SULFHYDRYL COMPOUNDS; TIME FACTORS;

EID: 0037111357     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(02)01043-2     Document Type: Article

References (39)

1. Hussain M.J., Maher J., Warnock T., Vats A., Peakman M., Vergani D. Cytokine overproduction in healthy first degree relatives of patients with IDDM. Diabetologia. 41:1998;343-349.
2. Rabinovitch A. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Diabetes. 43:1994;613-621.
3. Rabinovitch A., Suarez-Pinzon W.L. Cytokines and their roles in pancreatic islet β-cell destruction and insulin-dependent diabetes mellitus. Biochem. Pharmacol. 55:1998;1139-1149.
4. Reinhold D., Ansorge S., Schleicher E.D. Elevated glucose levels stimulate transforming growth factor-β1 (TGF-β1), suppress interleukin IL2, IL6 and IL10 production and DNA synthesis in peripheral blood mononuclear cells. Horm. Metab. Res. 28:1996;267-270.
5. Rapoport M.J., Mor A., Vardi P., Ramot Y., Winker R., Hindi A., Bistritzer T. Decreased secretion of Th2 cytokines precedes up-regulated and delayed secretion of Th1 cytokines in activated peripheral blood mononuclear cells from patients with insulin-dependent diabetes mellitus. J. Autoimmun. 11:1998;635-642.
6. Kakkar R., Mantha S.V., Radhi J., Prasad K., Kaira J. Antioxidant defence system in diabetic kidney a time course study. Life Sci. 60:1997;667-679.
7. Martin-Mateo M.C., Del Canto-Jafiez E., Barrero-Martinez M.J. Oxidative stress and enzyme activity in ambulatory renal patients undergoing continuous peritoneal dialysis. Ren. Fail. 20:1998;117-124.
8. Ross E.A., Koo L.C., Moberly J.B. Low whole blood and erythrocyte level of glutathione in hemodialysis and peritoneal dialysis patients. Am. J. Kidney Dis. 30:1997;480-494.
9. Bokemeyer C., Fels L.M., Dunn T., Voigt W., Gaedecke J., Schmoll H.J., Stolte H., Lentzen H. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti tumor activity. Br. J. Cancer. 74:1996;2036-2041.
10. Katiyar S.K., Korman N.J., Mukhtar H., Agarwal R. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J. Natl. Cancer Inst. 89:1997;556-566.
11. von Schnfeld J., Weisbrod B., Mller M.K. Silibinin, a plant extract with antioxidant and membrane stabilizing properties, protects exocrine pancreas from cyclosporin A toxicity. Cell. Mol. Life Sci. 53:1997;917-920.
12. Wenzel S., Stolte H., Soose M. Effects of silibinin and antioxidants on high glucose-induced alterations of fibronectin turnover in human mesangial cell cultures. J. Pharmacol. Exp. Ther. 279:1996;1520-1526.
13. Donoghue N., Yam P.T., Jiang X.M., Hogg P.J. Presence of closely spaced protein thiols on the surface of mammalian cells. Protein Sci. 9:2000;2436-2445.
14. Jiang X.M., Fitzgerald M., Grant C.M., Hogg P.J. Redox control of exofacial protein/disulfides by protein disulfide isomerase. J. Biol. Chem. 247:1999;2416-2423.
15. Tger M., Krning H., Thiel U., Ansorge S. Membrane-bound proteindisulfide isomerase (PDI) is involved in regulation of surface expression of thiols and drug sensitivity of B-CLL cells. Exp. Hematol. 25:1997;601-607.
16. Meister A. Glutathione metabolism. Methods Enzymol. 251:1995;3-7.
17. Dehmlow C., Murawski N., de Groot H. Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. Life Sci. 58:1996;1591-1600.
18. Drge W., Schulze-Osthoff K., Mihm S., Galter D., Schenk H., Eck H.P., Roth S., Gmnder H. Functions of glutathione and glutathione disulfide in immunology and immunopathology. FASEB J. 8:1994;1131-1138.
19. Fields J.A., Keshavarzian A., Eiznhamer G., Frommel T., Winship D., Holmes E.W. Low levels of blood and colonic glutathione in ulcerative colitis. Gastroenterology. 106:1994;A680.
20. Locher R., Suter P.M., Weyhenmeyer R., Vetter W. Inhibitory action of silibinin on low density lipoprotein oxidation. Arzneimittelforschung. 48:1998;236-239.
21. Richie J.P., Lang C.A., Chen T.S. Acetaminophen-induced depletion of glutathione and cysteine in the aging mouse kidney. Biochem. Pharmacol. 44:1992;129-135.
22. Usal A., Acarturk E., Yuregir G.T., Unlukurt I., Demirci C., Kurt H., Birand A. Decreased glutathione levels in acute myocardial infarction. Jpn. Heart J. 37:1996;177-182.
23. Julius M., Lang C.A., Gleiberman L., Harburg E., DiFranceisco W., Schork A. Glutathione and morbidity in a community-based sample of elderly. J. Clin. Epidemiol. 47:1994;1021-1026.
24. Soto C.P., Perez B.L., Favari L.P., Reyes J.L. Prevention of alloxan-induced diabetes mellitus in the rat by silymarin. Comp. Biochem. Physiol. C Pharmacol. Toxicol. Endocrinol. 119:1998;125-129.
25. Tger M., Dietzmann J., Thiel U., Neumann K.H., Ansorge S. Restoration of the cellular thiol status of peritoneal macrophages from CAPD patients by the flavonoids Silibinin and Silymarin. Free Radic. Res. 34:2001;137-151.
26. Hedley D.W., Chow S. Evaluation of methods for measuring cellular glutathione content using flow cytometry. Cytometry. 15:1994;349-358.
27. 2-induced changes in cell viability and cellular nonprotein thiol level of dissociated rat thymocytes. Jpn. J. Pharmacol. 71:1996;299-305.
28. Coates A., Tripp E. Comparison of two fluorochromes for flow cytometric assay of cellular glutathione content in human malignant melanoma. Melanoma Res. 5:1995;107-111.
29. Mardiney M. 3rd, Brown M.R., Fleisher T.A. Measurement of T-cell CD69 expression: a rapid and efficient means to assess mitogen- or antigen-induced proliferative capacity in normals. Cytometry. 26:1996;305-310.
30. Jacobson S.H., Moldeus P. Whole blood-, plasma- and red cell glutathione and cysteine in patients with kidney disease and during hemodialysis. Clin. Nephrol. 42:1994;189-192.
31. Ward N.E., Pierce D.S., Chung S.E., Gravitt K.R., O'Brian C.A. Irreversible inactivation of protein kinase C by glutathione. J. Biol. Chem. 273:1998;12558-12566.
32. Ceballos-Picot I., Witko-Sarsat V., Merad-Boudia M., Nguyen A.T., Thevenin M., Jaudon M.C., Zingraff J., Verger C., Jungers P., Descamps-Latscha B. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic. Biol. Med. 21:1996;845-853.
33. Tger M., Ittenson A., Franke A., Frey A., Gassen H.G., Ansorge S. Gamma-glutamyl transpeptidase-cellular expression in populations of normal human mononuclear cells and patients suffering from leukemias. Ann. Hematol. 70:1995;237-242.
34. Gatti G., Perucca E. Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 32:1994;614-617.
35. Lorenz D., Lucker P.W., Mennicke W.H., Wetzelsberger N. Pharmacokinetic studies with silymarin in human serum and bile. Methods Find. Exp. Clin. Pharmacol. 6:1984;655-661.
36. Schandalik R., Gatti G., Perucca E. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittelforschung. 42:1992;964-968.
37. Girndt M., Sester M., Sester U., Kaul H., Kohler H. Defective expression of B7-2 (CD 86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. Kidney Int. 59:2001;1382-1389.
38. Zi X.L., Mukhtar H., Agarwal R. Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin inhibition of mRNA expression of an endogenous tumor promoter TNFalpha . Biochem. Biophys. Res. Commun. 239:1997;334-339.
39. Saliou C., Rihn B., Cillard J., Okamoto T., Packer L. Selective inhibition of NF-kappaB activation by the flavonoid hepatoprotector silymarin in HepG2. Evidence for different activating pathways. FEBS Lett. 440:1998;8-12.